Pipeline

^*Collaboration Partners: Biogen Inc. and Shionogi for zuranolone
^**Sage plans to discontinue commercial availability of ZULRESSO in the U.S. as of December 31, 2024.
^***In July 2024, we announced discontinuation of clinical development of SAGE-324 in ET. Sage is evaluating next steps, if any, for other potential indications.

Please refer to the U.S. Prescribing Information for ZULRESSO and the U.S. Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result in approval by a health authority.